Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra- and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of inflammation, and atherosclerosis. Three PPARs, namely α, δ, and γ have been identifi ed with distinct tissue distribution patterns and metabolic functions. PPAR-α is predominantly expressed in brown adipose tissue, liver, kidney, duodenum, heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-γ is highly expressed in brown and white adipose tissues and, to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-δ shows a widespread tissue distribution but its regulation and functions are not yet known. Considerable evidence indicates that PPARs (PPAR-α and PPAR-γ ) have beneficial effects in infl ammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, fi brinolysis, and modulation of monocyte-derived macrophages. In this review, the general and specific roles of the PPAR isotypes and their implications in the control of vascular inflammation and atherosclerosis are discussed.
Araki K., Yachi M., Hagisawa Y., Tanaka N., Isobe A., Sakakibara S., Ohsumi J., TsurutaF., Izumi T., Fujita T., Fujiwara T., Horikoshi H. (2000). Antidiabetic characterization of CS-011: A new thiazolidinedione with potent insulin-sensitizing activity. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 425.
2.
Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou JP, Staels B., Auwerx J., Laville M., Vidal H. (1997). Tissue distribution and quantifi cation of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes46: 1319—1327.
3.
Benson S., Wu J., Padmanabhan S., Kurtz TW, Pershadsingh HA (2000). Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator Troglitazone. Am J Hypertens13: 74—82.
4.
Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S., Leff T., White AD, Creger P., Pape ME, Rea TJ, Newton RS (1998). A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res39: 17—30.
5.
Bishop-Bailey D. (2000). Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol129: 823—834.
6.
Bishop-Bailey D., Hla T. (1999). Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ 12,14 prostaglandin J2. J Biol Chem274: 17042—17048.
7.
Blanchard SG , Kliewer SA, Parks DJ, Way JM (2000). The novel tyrosine-based PPAR-gamma agonist GI262570 shows preferential binding to PPAR-gamma complexed with RXR-alpha and CBP . Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 391.
8.
Boisvert WA, Santiago R., Curtiss LK, Terkeltaub RA (1998). A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL-receptor defi cient mice. J Clin Invest101: 353—363.
9.
Boring L., Gosling J., Chensue SW, Kunkel SL, Farese RVJr, Broxmeyer HE, Charo IF (1997). Impaired monocyte migration and reduced type I (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest100: 2552—2561.
10.
Braissant O. , Foufelle F., Scotto C., Dauca M., Wahli W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPARα, β, and - γ in the adult rat. Endocrinology137: 354—366.
11.
Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., Page M., Kaltschmidt C., Baeuerle PA, Neumeier D. (1996). Activated transcription factor nuclear factor-κ B is present in the atherosclerotic lesion. J Clin Invest97: 1715—1722.
12.
Bunte T., Hahman HW, Hellwig N., Hau U., Becker D., Dyckmans J., Keller HE, Schieffer HJ (1993). Effect of fenofi brate on angiographically examined coronary atherosclerosi s and left ventricular function in hypercholesterolemic patients. Atherosclerosis98: 127—138.
13.
Chen N-G., Sarabia SF, Malloy PJ, Zhao X-Y., Feldman D., Reaven GM (1999). PPAR-γ agonists enhance human vascular endothelial adhesivenes s by increasing ICAM-1 expression. Biochem Biophys Res Commun263: 718—722.
14.
Chinetti G., Griglio S., Antonucci M., Torra IP, Delerive P., Majd Z., Fruchart J-C., Chapman J., Najib J., Staels B. (1998). Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem273: 25573—25580.
15.
Collins AR, Meehan WP, Hsueh WA, Palinski W., Law RE (2000). Troglitazone inhibits atherosclerotic lesion formation and macrophage accumulation in male LDLR-/- mice fed high fat and high fructose diets. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 221.
16.
Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000). Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloidstimulated proinfl ammatory responses and neurotoxicity by PPARgamma agonists. JNeuroscience20: 558—567.
17.
Cominacini L., Garbin U., Pasini AF, Davoli A., Campagnola M., Rigoni A., Tosetti L., Lo Cascio V (1999). The expression of adhesion molecules on endothelial cells in inhibited by troglitazone through its antioxidant activity. Cell Adhesion Commun7: 223—231.
18.
Delerive P. , Martin-Nizard F., Chinetti G., Trottein F., Fruchart JC, Najib J., Duriez P., Staels B. (1999). Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res85: 394—402.
19.
Devchand PR , Keller H., Peters JM, Vazquez M., Gonzalez FJ, Wahli W. (1996). The PPAR-α-leukotriene B4 pathway to infl ammation control . Nature384: 39—43.
20.
Djouadi F., Weinheimer CJ, Saffi tz JE, Pitchford C., Bastin J., Gonzalez FJ, Kelly DP (1998). A gender-related defect in lipid metabolism and glucose homeostasi s in peroxisome proliferator-activated receptor α-defi cient mice. J Clin Invest102: 1083—1091.
21.
Ericsson CG , Hamsten A., Nilsson J., Grip L., Svane B., De Fair U. (1996). Angiographi c assessment of effects of bezafi brate on progression of coronary artery disease in young male postinfarction patients. Lancet347: 849— 853.
22.
Forman BM, Chen J., Evans RM (1997). Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA94: 4312—4317.
23.
Forman BM, Tontonoz P., Chen J., Brun RP, Spiegelman BM, Evans RM (1995). 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell83: 803—812.
24.
Frick MH, Syvanne M., Nieminen MS, Kauma H., Majahalme S., Virtanen V., Kesaniemi YA, Pasternack A., Taskinen MR (1997). Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels in HDL cholesterol. Lopid Coronary Trial (LOCAT) study group. Circulation96: 2137—2143.
25.
Goetze S., Xi XP, Graf K., Fleck E., Hsueh WA, Law RE (1999). Troglitazone inhibits angitensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett452: 277—282.
26.
Grossman SL , Lessem J. (1997). Mechanisms and clinical effects of thiazolidinediones. Exp Opin Invest Drugs6: 1025—1040.
27.
Gu L., Okada Y., Clinton SK, Gerard C., Sukhova GK, Libby P., Rollins BJ (1998). Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice . Mol Cell2: 275— 281.
28.
Hashimoto T. , Fujita T., Usuda N., Cook W., Qi C., Peters JM, Gonzalez FJ, Yeldandi AV, Rao MS, Reddy JK (1999). Peroxisome and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor α and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem274: 19228—19236.
29.
Hattori Y., Hattori S., Kasai K. (1999). Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension33: 943—948.
30.
He T-C. , Chan TA, Vogelstein B., Kinzler KW (1999). PPARδ is an APCregulated target of nonsteroidal anti-inflammatory drugs . Cell99: 335—345.
31.
Inoue I., Shino K., Noji S., Awata T., Katayama S. (1998). Expression of peroxisome proliferator-activated receptor α (PPAR-α) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun246: 370—374.
32.
Jiang C., Ting AT, Seed B. ( 1998). PPAR-gamma agonists inhibit production of monocyte infl ammatory cytokines. Nature391: 82—86.
33.
Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., Mizuno K., Fujita T., Tsukamoto K., Watanabe T. (1999). Thiazolidinediones down-regulate plasminogen activator inhibitor type-1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelialfunction. Biochem Biophys Res Commun258: 431—435.
34.
Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J., Wu MS, Meurer R., Forrest MJ, Conner MW, Cascieri MA, Moller DE (1998). Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology139: 4920—4927.
35.
Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P., Wahli W., Willson TM, Lenhard JM, Lehmann JM (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ . Proc Natl Acad Sci USA94: 4318—4323.
36.
Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker MG, Wahli W. (1997). Fatty acids, eicosanoids, and hypolipidemic agents identifi ed as ligands of peroxisome proliferator-activated receptors by co-activator-dependen t receptor ligand assay. Mol Endocrinol11: 779—791.
37.
Law RE, Goetze S., Xi XP, Jackson S., Kawano Y., Demer L., Fishbein MC, Meehan WP, Hsueh WA (2000). Expression and function of PPAR-γ in rat and human vascular smooth muscle cells. Circulation101: 1311—1318.
38.
Law RE, Meehan WP, Xi XP, GrafK., Wuthrich DA, Coats W., Faxon D., Hsueh WA (1996). Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest98: 1897—1905.
39.
Leibowitz MD , Fievet C., Hennuyer N., Peinado-Onsurb e J., Duez H., Berger J., Cullinan CA, Sparrow CP, Baffi c J., Berger GD, Santini C., Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J. (2000). Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett473: 333—336.
40.
Li Y., Leung LK, Glauert HP, Spear BT (1996). Treatment of rats with the peroxisome proliferator ciprofi brate results in increased liver NF-κB activity. Carcinogenesis17: 2305—2309.
41.
Lim H., Dey SK (2000). PPARδ functions as a prostacyclin receptor in blastocyst implantation. TEM11: 137—142.
42.
Lim H., Gupta RA, Ma W., Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK (1999). Cyclo-oxygenase-2-derive dprostacyclin mediates embryo implantation in the mouse via PPARδ. Genes Dev13: 1561—1574.
43.
Lin Q., Ruuska SE, Shaw NS, Dong D., Noy N. (1999). Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry38: 185—190.
44.
Loviscach M. , Henry RR (1999). Clinical signifi cance of proliferator-activated receptors in health and disease. Medscape DiabetesEndocrinol1—14.
45.
Marx N., Bourcier T., Sukhova GK, Libby P., Plutzky J. (1999). PPAR-γ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-γ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol19: 546—551.
46.
Marx N., Mach F., Sauty A., Leung JH, Sarafi MN, Ransohoff RM, Libby P., Plutzky J., Luster AD (2000). Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ -induced expression of the T-cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol164: 6503—6508.
47.
Marx N., Schonbeck U., Lazar MA, Libby P., Plutzky J. (1998). Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res83: 1097—1103.
48.
Marx N., Sukhova GK, Collins T., Libby P., Plutzky J. (1999). PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation99: 3125—3131.
49.
Medicherla S., Dey D., Neogi P., Lakner FJ, Nag B. (2000). CLX-0921: A new PPAR-gamma agonist anti-diabetic thiazolidinedione compound. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 475.
50.
Meertens LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP (1998). A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha . EMBO J17: 6972— 6978.
51.
Michalik L., Wahli W. (1999). Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions. Curr Opin Biotechnol10: 564— 570.
52.
Miles PDG , Barak Y., He W., Evans RM, Olefsky JM (2000). Improved insulin-sensitivity in mice heterozygou s for PPAR-γ defi ciency. J Clin Invest105: 287—292.
53.
Minamikawa J. , Tanaka S., Yamauchi M., Inoue D., Koshiyama H. (1998). Potent inhibitory effect of troglitazone on carotid arterial wall thicknes s in type-2 diabetes. J Clin Endocrinol Metab83: 1818—1820.
54.
Mizushige K. , Noma T., Yao L., Yu Y., Kiyomoto H., Hosomi N., Fukui T., Kimura S., Abe Y., Matsuo H. (2000). Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima fatty rats. J Cardiovasc Pharmacol35: 150—155.
55.
Motojima K. , Passilly P., Peters JM, Gonzalez FJ, Latruffe N. (1998). Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner . J Biol Chem273: 16710—16714.
56.
Murao K., Imachi H., Momoi A., Sayo Y., Hosokawa H., Sato M., Ishida T., Takahara J. (1999). Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells . FEBS Lett454: 27—30.
57.
Nag B. (2000). CLX-0901: A new class of orally active anti-diabetic compound. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association. Abstract 479.
58.
Nagy L., Tontonoz P., Alvarez JGA, Chen H., Evans RM (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ . Cell93: 229—240.
59.
Naitoh T., Nakabeppu H., Kamon J., Yotsumoto T., Kitahara M., Tsuruzoe N., Ohdoi K., Kato K., Suzuki M. (2000). NIP-221 is a novel and potent thiazolidinedione-base d peroxisome proliferator-activated receptor (PPAR) gamma ligand with long biological half-time. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 480.
60.
Newby AC, Zaltsman AB (1999). Fibrous cap formation or destruction— The critical importance of vascular smooth muscle proliferation, migration, and matrix formation. Cardiovasc Res41: 345—360.
61.
Nilakantan V., Spear BT, Glauert HP (1998). Liver-specifi c catalase expression in transgenic mice inhibits NF-kappa B activation and DNA synthesis induced by the peroxisome proliferator ciprofi brate. Carcinogenesis19: 631—637.
62.
Ohta MY, Nagai Y., Takamura T., Nohara E., Kobayashi K. (2000). Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells. Metabolism: Clin Exp49: 163—166.
63.
Pasceri V., Wu HD, Willerson JT, Yeh ETH (2000). Modulation of vascular infl ammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators . Circulation101: 235—238.
64.
Plutzky J. (1999). Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol84: 15J—20J.
65.
Pulaski JT, Davis JA, Yuille K., Johnson JH (2000). The antidiabetic effects of CI-1037/CS011, a new thiazolidinedione. Program and Abstracts of the 60th Scientifi c sessions of the American Diabetes Association; June 9—13, San Antonio, Texas. Abstract 496.
66.
Rajavashisth T., Qiao JH, Tripathi S., Tripathi J., Mishra N., Hua M., Wang XP, Loussararian A., Clinton S., Libby P., Lusis A. (1998). Heterozygous osteopetrotic (op) mutation reduces atherosclerosi s in LDL receptor-deficient mice. J Clin Invest101: 2702—2710.
67.
Ricote M., Li AC, Willson TM, Kelly CJ, Glass CK (1998). The peroxisome proliferator-activate d receptor-gamm a is a negative regulator of macrophag e activation. Nature391: 79—82.
68.
Rusyn I., Tsukamoto H., Thurman RG (1998). WY-14 643 rapidly activates nuclear factor kappaB in kupffer cells before hepatocytes. Carcinogenesis19: 1217—1222.
69.
Schecter AD , Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M., Giesen PL, Nemerson Y., Taubman MB (1997). Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem272: 28568—28573.
70.
Shibata T., Matsui K., Nagao K., Shinkai H., Yonemori F., Wakitani K. (1999). Pharmacological profi les of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol364: 211—219.
71.
Shu H., Wong B., Zhou G., Li Y., Berger J., Woods JW, Wright SD, Cai T-Q. (2000). Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocyte THP-1 cells. Biochem Biophys Res Commun267: 345—349.
72.
Spencer CM, Markham A. (1997). Troglitazone. Drugs54: 89—101.
73.
Staels B., Auwerx J. (1998). Regulation of apo A-1 gene expression by fi brates . Atherosclerosis137: S19—S23.
74.
Staels B., Dallongeville J., Auwerx J., Schoonjans K., LeitersdorfE., Fruchart JC (1998). Mechanism of action of fi brates on lipid and lipoprotein metabolism. Circulation98: 2088—2093.
75.
Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra IP, Delerive P., Faddel A., Chinetti G., Fruchart JC, Najib J., Maclouf J., Tedgui A. (1998). Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARβ activattors. Nature393: 790—793.
76.
Su CG, Wen X., Bailey ST, Jiang W., Rangwala SM, Keilbaugh SA, Flanigan A., Murthy S., Lazar MA, Mitchell A., Wu GD (1999). A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial infl ammatory response. J Clin Invest104: 383—389.
77.
Takagi T., Yoshida K., Akasaka T., Hozumi T., Yamamuro A., Morioka S. (1999). Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol33: 100A.
78.
Thieringer R., Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L., Moller DE, Wright SD, Berger J. (2000). Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol164: 1046—1054.
79.
Tontonoz P. , Nagy L., Avarez JGA, Thomazy VA, Evans RM (1998). PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell93: 241—252.
